Aptorum Group Limited (APM)

Market Cap	41.06M
Revenue (ttm)	1.54M
Net Income (ttm)	-25.05M
Shares Out	35.70M
EPS (ttm)	-0.72
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	148,062
Open	1.23
Previous Close	1.24
Day's Range	1.12 - 1.27
52-Week Range	0.86 - 2.72
Beta	0.03
Analysts	Buy
Price Target	15.30 (+1,230.4%)
Earnings Date	Jul 29, 2022

About APM

Aptorum Group Limited, a biopharmaceutical company, engages in the discovery, development, and commercialization of therapeutic products for the treatment of infectious diseases and cancer. The company operates in the Therapeutics and Non-Therapeutics segments. Its pipeline products include SACT- 1 for neuroblastoma and other cancer types; SACT-COV19 for the treatment of coronavirus disease; ALS-4 to treat bacterial infections caused by staphylococcus aureus, including MRSA; and ALS-1 to treat viral infections caused by influenza virus A. The c...

• Industry: Biotechnology
• IPO Date: Dec 18, 2018
• Employees: 26
• Stock Exchange: NASDAQ
• Ticker Symbol: APM

Full Company Profile

Financial Performance

Financial Statements

Analyst Forecast

According to 5 analysts, the average rating for APM stock is "Buy." The 12-month stock price forecast is 15.3, which is an increase of 1,230.43% from the latest price.

Price Target

$15.3

(1,230.43% upside)

Analyst Consensus: Buy

Stock Forecasts